Corticotropin-releasing factor (CRF) plays a key role in neuroendocrine regulation of hypothalamo-pituitary-adrenal axis under normal condition and stress by binding to CRF receptor1 (CRFR1). CRF and its receptors have been reported in many types of tumors. Little is known about the role of CRF in the development of glioma. And lincRNA-p21 was reported to act as a role in progression of some cancers. The aim of the present study was to investigate the levels of CRF in glioma, and explore the link between CRF and lincRNA-p21 in this disease. In this study, we found CRF mRNA expression was significantly down-regulated in glioma mice. Moreover, CRF could suppress the proliferation of glioma cells and promote the expression of lincRNA-p21. Afterwards, lincRNA-p21 repressed the proliferation and invasion of glioma cells, which was reversed by miR-34c targeted with 3'-UTR. Furthermore, miR-34c decreased the expression of CRFR1 by binding with the 3'-UTR, which interact with CRF to inhibit the proliferation of glioma cells. Together, these results CRF plays as an important role in glioma progression and metastasis through activation of lincRNA-p21, providing a novel insight for the pathogenesis and underlying therapeutic target for glioma.
Keywords: CRF; CRFR1; Glioma; LINCRNA-p21; miR-34c.
Copyright © 2018 Elsevier Inc. All rights reserved.